Fluoxastrobin

Solubilities (20 °C, g/L): dichloromethane >250; xylene 38.1; isopropanol 6.7; n-heptane 0.04

In water, 2.56 mg/L at 20 °C, unbuffered

In water, 2.29 mg/L at 20 °C (pH 7)

103-108 °C

White, crystalline soild ... insoluble in water (0.0023 g/L in water at pH 7) ... highly soluble in dichloromethane, polyethylene glycol 400, acetone, ethyl acetate, acetonitrile, and dimethylsulfoxide ... mp: 103-105 °C ... log Kow = 2.85 at 20 °C. It does not dissociated in water at pH 4 to 9 ... vapor pressure = 5.63X10-10 Pa /SRC: 4.22X10-12 mm Hg/ at 20 °C /Technical/

Warning

H317 (96.5%): May cause an allergic skin reaction [Warning Sensitization, Skin]；H400 (100%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]；H410 (22.4%): Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard]

P261, P272, P273, P280, P302+P352, P321, P333+P317, P362+P364, P391, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 85 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.；Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.

Council Directive (EEC) No 414/1991 (Repealed by Reg. EC No 1107/2009 (amended))

Fluoxastrobin is listed in the dataset of EPA Human Health Benchmarks for Pesticides under the Safe Drinking Water Act (40 eCFR 141)

08/44/EC, Reg. (EU) 2018/917, Reg. (EU) 2019/707, Reg. (EU) 2020/869, Reg. (EU) 2021/745, Reg. (EU) 2022/708, Reg. (EU) 2023/918, Reg. (EU) 540/2011

(E)-Fluoxastrobin: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Tolerances are established for residues of fluoxastrobin, including its metabolites and degradates, in or on the commodities in the table below. Compliance with the tolerance levels specified below is to be determined by measuring only fluoxastrobin, (1E)-[2-[[6-(2-chlorophenoxy)-5-fluoro-4-pyrimidinyl]oxy]phenyl](5,6-dihydro-1,4,2-dioxazin-3-yl)methanone O-methyloxime and its Z isomer, (1Z)-[2-[[6-(2-chlorophenoxy)-5-fluoro-4-pyrimidinyl]oxy]phenyl](5,6-dihydro-1,4,2-dioxazin-3-yl)methanone O-methyloxime, calculated as the stoichiometric equivalent of fluoxastrobin. [Table#7645]

Tolerances are established for residues of fluoxastrobin, including its metabolites and degradates, in or on the commodities in the table below. Compliance with the tolerance levels specified below is to be determined by measuring only fluoxastrobin, (1E)-[2-[[6-(2-chlorophenoxy)-5-fluoro-4-pyrimidinyl]oxy]phenyl](5,6-dihydro-1,4,2-dioxazin-3-yl)methanone O-methyloxime, its Z isomer, (1Z)-[2-[[6-(2-chlorophenoxy)-5-fluoro-4-pyrimidinyl]oxy]phenyl](5,6-dihydro-1,4,2-dioxazin-3-yl)methanone O-methyloxime, and its phenoxy-hydroxypyrimidine, 6-(2-chlorophenoxy)-5-fluoro-4-pyrimidinol, calculated as the stoichiometric equivalent of fluoxastrobin. [Table#7646]

Tolerances are established for the indirect or inadvertent residues of fluoxastrobin, including its metabolites and degradates, in or on the commodities in the table below, when present therein as a result of the application of fluoxastrobin to the growing crops listed in paragraph (a)(1) of this section. Compliance with the tolerance levels specified below is to be determined by measuring only fluoxastrobin, (1E)-[2-[[6-(2-chlorophenoxy)-5-fluoro-4-pyrimidinyl]oxy]phenyl](5,6-dihydro-1,4,2-dioxazin-3-yl)methanone O-methyloxime and its Z isomer, (1Z)-[2-[[6-(2-chlorophenoxy)-5-fluoro-4-pyrimidinyl]oxy]phenyl](5,6-dihydro-1,4,2-dioxazin-3-yl)methanone O-methyloxime, calculated as the stoichiometric equivalent of fluoxastrobin. [Table#7647]

Store in original container and keep tightly closed. Store in a cool dry place. /Evito 480 SC Fungicide/

Safe Storage of Pesticides. Always store pesticides in their original containers, complete with labels that list ingredients, directions for use, and first aid steps in case of accidental poisoning. Never store pesticides in cabinets with or near food, animal feed, or medical supplies. Do not store pesticides in places where flooding is possible or in places where they might spill or leak into wells, drains, ground water, or surface water. /Residential users/

If a spill occurs, clean it up promptly. Don't wash it away. Instead, sprinkle the spill with sawdust, vermiculite, or kitty litter. Sweep it into a plastic garbage bag, and dispose of it as directed on the pesticide product label./Residential users/

After Applying a Pesticide, Indoors or Outdoors. To remove pesticide residues, use a bucket to rinse tools or equipment three times, including any containers or utensils that you used when mixing the pesticide. Then pour the rinsewater into the pesticide sprayer and reuse the solution by applying it according to the pesticide product label directions. After applying any pesticide wash your hands and any other parts of your body that may have come in contact with the pesticide..To prevent tracking pesticides inside, remove or rinse your boots or shoes before entering your home. Wash any clothes that have been exposed to a lot of pesticide separately from your regular wash. /Residential users/

SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational harm/injury/toxicity or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal and plant life; and conformance with environmental and public health regulations.

Wastes resulting from the use of this product may be disposed of on site or at an approved waste disposal facility. /Evito 480 SC Fungicide/

Empty containers should be triple rinsed. Do not reuse empty containers. Offer for recycling or reconditioning, or puncture and dispose of in a sanitary landfill, or by other procedures approved by state and local authorities. /Evito 480 SC Fungicide/

Do not contaminate /surface or ground/ water when disposing of equipment washwater rinsate. /Evito 480 SC Fungicide/

For more Disposal Methods (Complete) data for Fluoxastrobin (6 total), please visit the HSDB record page.

Use this product only in accordance with its labeling and with the Worker Protection Standard, 40 CFR part 170. /Evito 480 SC Fungicide/

Do not apply this product in a way that will contact workers or other persons, either directly or through drift. Only protected handlers may be in the area during application. /Evito 480 SC Fungicide/

This pesticide is toxic to fish and aquatic invertebrates. ... Do not apply directly to water or to areas where surface water is present or to intertidal areas below the mean high water mark, or other sensitive areas that may be exposed to spray drift.. /Evito 480 SC Fungicide/

Do not enter or allow worker entry into treated areas during the restricted-entry interval (REI) of 12 hours. /Evito 480 SC Fungicide/

For more Preventive Measures (Complete) data for Fluoxastrobin (16 total), please visit the HSDB record page.

Tolerances are established for residues of fluoxastrobin, including its metabolites and degradates, in or on the commodities in the table below. Compliance with the tolerance levels specified below is to be determined by measuring only fluoxastrobin, (1E)-[2-[[6-(2-chlorophenoxy)-5-fluoro-4-pyrimidinyl]oxy]phenyl](5,6-dihydro-1,4,2-dioxazin-3-yl)methanone O-methyloxime and its Z isomer, (1Z)-[2-[[6-(2-chlorophenoxy)-5-fluoro-4-pyrimidinyl]oxy]phenyl](5,6-dihydro-1,4,2-dioxazin-3-yl)methanone O-methyloxime, calculated as the stoichiometric equivalent of fluoxastrobin. [Table#7642]

Tolerances are established for residues of fluoxastrobin, including its metabolites and degradates, in or on the commodities in the table below. Compliance with the tolerance levels specified below is to be determined by measuring only fluoxastrobin, (1E)-[2-[[6-(2-chlorophenoxy)-5-fluoro-4-pyrimidinyl]oxy]phenyl](5,6-dihydro-1,4,2-dioxazin-3-yl)methanone O-methyloxime, its Z isomer, (1Z)-[2-[[6-(2-chlorophenoxy)-5-fluoro-4-pyrimidinyl]oxy]phenyl](5,6-dihydro-1,4,2-dioxazin-3-yl)methanone O-methyloxime, and its phenoxy-hydroxypyrimidine, 6-(2-chlorophenoxy)-5-fluoro-4-pyrimidinol, calculated as the stoichiometric equivalent of fluoxastrobin. [Table#7643]

Tolerances are established for the indirect or inadvertent residues of fluoxastrobin, including its metabolites and degradates, in or on the commodities in the table below, when present therein as a result of the application of fluoxastrobin to the growing crops listed in paragraph (a)(1) of this section. Compliance with the tolerance levels specified below is to be determined by measuring only fluoxastrobin, (1E)-[2-[[6-(2-chlorophenoxy)-5-fluoro-4-pyrimidinyl]oxy]phenyl](5,6-dihydro-1,4,2-dioxazin-3-yl)methanone O-methyloxime and its Z isomer, (1Z)-[2-[[6-(2-chlorophenoxy)-5-fluoro-4-pyrimidinyl]oxy]phenyl](5,6-dihydro-1,4,2-dioxazin-3-yl)methanone O-methyloxime, calculated as the stoichiometric equivalent of fluoxastrobin. [Table#7644]

... Restricted-entry interval (REI) of 12 hours. Do not enter or allow worker entry into treated areas during the restricted-entry interval (REI) of 12 hours. PPE required for early entry to treated areas that is permitted under the Worker Protection Standard and that involves contact with anything that has been treated, such as plants, soil, or water is: long-sleeved shirt and long pants or coveralls, shoes plus socks, and chemical resistant gloves made of any waterproof material, such as nitrile, butyl, neoprene, and/or barrier laminate. /Evito 480 SC Fungicide/

Applicators and other handlers must wear long-sleeved shirt and long pants, shoes plus socks, and chemical resistant gloves made of any waterproof material, such as nitrile, butyl, neoprene and/or barrier laminate. /Evito 480 SC Fungicide/

... Restricted-entry interval (REI) of 12 hours. Do not enter or allow worker entry into treated areas during the restricted-entry interval (REI) of 12 hours. PPE required for early entry to treated areas that is permitted under the Worker Protection Standard and that involves contact with anything that has been treated, such as plants, soil, or water is: long-sleeved shirt and long pants or coveralls, shoes plus socks, and chemical resistant gloves made of any waterproof material, such as nitrile, butyl, neoprene, and/or barrier laminate. /Evito 480 SC Fungicide/

TERRESTRIAL FATE: Based on a classification scheme(1), a Koc value range of 424 to 1582(2), indicates that fluoxastrobin is expected to have moderate to low mobility in soil(SRC). Volatilization of fluoxastrobin from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 1.1X10-12 atm-cu m/mole(SRC), based upon its vapor pressure, 4.5X10-12 mm Hg(2), and water solubility, 2.56 mg/L(2). Fluoxastrobin is not expected to volatilize from dry soil surfaces(SRC) based upon its vapor pressure(2). Biodegradation of fluoxastrobin under aerobic conditions could take several months to several years, depending on the soil texture(3).

AQUATIC FATE: Based on a classification scheme(1), a Koc value range of 424 to 1582(2), indicates that fluoxastrobin is expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces is not expected(3) based upon an estimated Henry's Law constant of 1.1X10-12 atm-cu m/mole(SRC), derived from its vapor pressure, 4.5X10-12 mm Hg(2), and water solubility, 2.56 mg/L(2). According to a classification scheme(4), an estimated BCF of 36(SRC), from its log Kow of 2.86(2) and a regression-derived equation(5), suggests the potential for bioconcentration in aquatic organisms is moderate(SRC). Fluoxastrobin is stable toward abiotic hydrolysis in sterile buffered solutions at pH 4, 7 and 9 at 50 °C(6). Under aerobic aquatic conditions, a half-life of several days was reported(2).

ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), fluoxastrobin, which has a vapor pressure of 4.5X10-12 mm Hg at 20 °C(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase fluoxastrobin may be removed from the air by wet or dry deposition(SRC).

AEROBIC: Biodegradation of fluoxastrobin under aerobic conditions could take several months to several years, depending on the soil texture. A half-life of 29.4 days in sandy loam to 393 days in loamy sand (average half-life of 141 days) has been reported(1). Under aerobic aquatic conditions, a half-life of several days was reported(2).

An estimated BCF of 36 was calculated in fish for fluoxastrobin(SRC), using a log Kow of 2.86(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is moderate(SRC).

The Henry's Law constant for fluoxastrobin is estimated as 1.1X10-12 atm-cu m/mole(SRC) derived from its vapor pressure, 4.5X10-12 mm Hg(1), and water solubility, 2.56 mg/L(1). This Henry's Law constant indicates that fluoxastrobin is expected to be essentially nonvolatile from water surfaces(2). Fluoxastrobin is not expected to volatilize from dry soil surfaces(SRC) based upon its vapor pressure(1).

/LABORATORY ANIMALS: Acute Exposure/ A preliminary study was conducted in which a single 20 uCi (200 ug) dose of (14)C HEC 5725 (/fluoxastrobin/ lot no. 12250/39, purity >99%) was administered intravenously or dermally (EC 100 formulation) to one male rhesus monkey. The intravenous dose served as a reference for 100% bioavailability. For the main study a single 15 uCi (150 ug) dose of (14)C HEC 5725 (lot no. 12250/39, purity >99%) was administered dermally (EC 100 formulation) to five male rhesus monkeys. The dermal application was for eight hours. Excreta were monitored for up to 192 hours (intravenous dose) or 120 hours (dermal application). There were no significant adverse effects that could be attributed to the test article. One monkey vomited and another (both in the dermal exposure group; main study) exhibited soft stools at 4 hours post-application. Actual doses were 195 ug (iv), 172 ug (preliminary dermal), and 148 ug (main dermal). These doses correspond to 60.9 ug/kg, 7.17 ug/ sq cm, and 6.12 ug/ sqcm; only 2.5, 14, and 1% from nominal, respectively. ...

/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ In a subacute (28-day) study, HEC 5725 (/fluoxastrobin/ 95.1% a.i. (98.8 % E-isomer, 1.2 % Z-isomer), Batch # 06261/0008) and HEC 5725 A [ /fluoxastrobin/ 97.7% a.i. (62.5% E-isomer, 35.2% Z-isomer), Batch # NLL 6112-31] were each administered to 5 Wistar rats/sex/dose in the diet at concentrations of 0, 100, 500, 2500, or 10,000 ppm (except that HEC 5725A had no 0 ppm group). In males, these doses were equivalent to 0, 8.3, 41.5, 209.7, or 1005.6 mg/kg bw/day HEC 5725 and in females to 0, 10.0, 52.7, 261.2, or 1451.7 mg/kg bw/day. Doses were equivalent to 8.5, 42.1, 226.6, or 1001.5 mg/kg bw/day HEC 5725A in males, and to 8.8, 47.7, 247.6, or 1419.5 mg/kg bw/day in females. Actual mean test intake of HEC 5725A may have been up to 20% less than the nominal values due to limited stability in the diet resulting in test compound levels as low as 60% in dietary mixtures at the end of the weekly feeding periods. There were no treatment-related effects on mortality, clinical signs, hematology, or gross pathology. There was a marginal decrease in body weight of high-dose male rats treated with both HEC 5725 and HEC 5725 A and in body weight gain of all high-dose groups, male and female, treated with both test substances. There were no toxicologically significant effects on urinalysis parameters and no toxicologically significant effects were seen on absolute or relative organ weight. Adrenal cortical cytomegaly with fine vacuolization was seen in all high dose groups (male and female) treated with both test substances and in one female each at 2500 ppm in the HEC 5725 and HEC 5725 A groups. The effects of HEC 5725 and HEC 5725 A were very similar despite the stability problem with the latter. The LOAEL for HEC 5725 and HEC 5725 A in male rats is 10,000 ppm (1005.6 mg/kg/day and 1001.5 mg/kg bw/day, respectively) and for female rats is 2500 ppm (261.2 mg/kg bw/day and 247.6 mg/kg bw/day for HEC 5725 and HEC 5725 A, res

/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ In a 4-week oral toxicity study HEC 5725 N (99.3% a.i., (/fluoxastrobin/ 90% E-isomer, 10% Z-isomer) batch no. NLL6112-24) in Altromin 1321 diet (with 1% peanut oil) was administered to five Wistar HsdCpb:WU (SPF) rats/sex/dose at dose levels of 0, 100, 500, 2500, or 10,000 ppm (0, 9.7, 49.4, 237.1, or 1016.8 mg/kg/day for males and 0, 8.6, 43.4, 221.6, or 891.8 mg/kg/day for females, respectively). In addition, five additional rats/sex/dose were used to conduct immunotoxicity assays. ... No effects were observed on mortality, clinical signs, or in immunotoxicity assays. Food and water consumption of treated animals were comparable to the controls; however, overall body weight was slightly decreased in females in the 10,000 ppm group, ranging from 8% less than the control group on day 7 to 13% less on day 28. There were slight dose-related decreases in female body weight gain at doses $500 ppm (83, 79, and 72% of the control for the 500, 2500, or 10,000 ppm dose groups, respectively). The decreases appeared to correlate with the lower food efficiency throughout the study in females. Males administered 10,000 ppm showed decreases in hemoglobin (6%, p<0.01) and mean corpuscular hemoglobin concentration (MCHC) (2%, p<0.05) compared with the controls. Females administered 10,000 ppm had a decrease in hemoglobin (9%, p<0.01). In addition, the females showed slight decreases in hematocrit 6, 6 and 8% than the controls for the 500, 2500 and 10,000 ppm groups, respectively and did not appear to be dose or treatment-related. Decreases in enzyme activities of blood and liver and increases in P-450 activity were within the normal range of variation. Urine calcium concentrations were elevated to 384 and 288% of the control values in the males and females that were treated with 10,000 ppm HEC 5725N. ... There were no absolute organ weight changes observed; however, relative liver weight of the highest dose groups of males a

/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ In a 9-week oral toxicity study HEC 5725 (Fluoxastrobin , 97.1% a.i., Batch # NLL6112-(20-22)) was administered to 10 male rats/dose in the diet at dose levels of 0, 62.5, 125, 1000, or 8000 ppm (equivalent to 0, 3.6, 7.3, 59.7, or 520.3 mg/kg bw/day) and to 10 female rats/dose at dose levels of 0, 125, 250, 2000, or 16,000 ppm (equivalent to 0, 9.0, 18.3, 146.3, or 1544.2 mg/kg bw/day). Satellite groups were administered 1% NH4Cl in the drinking water (to assess the effects of urinary acidification) ad libitum and consisted of 10 male rats/dose with test substance administered in the diet at dose levels of 0 or 8000 ppm (equivalent to 0 or 476.5 mg/kg bw/day) and 10 female rats/dose with HEC 5725 administered at dose levels of 0 or 16,000 ppm (equivalent to 0 or 1590.6 mg/kg bw/day). There were no treatment-related effects on mortality, clinical signs, organ weight, or gross pathology. There was a marginal decrease in body weight and body weight gain in high-dose female rats. Blood parathyroid hormone activity showed no HEC 5725-related changes. Serum Vitamin D concentration showed no toxicologically significant differences among groups. The main target organs appear to be the adrenal cortex, kidney and possibly bone. This study tested whether the increased calcium excretion and calcium oxalate crystal formation in high dose animals was a result of the HEC 5725-induced pH changes, by acidifying the urine via administration of 1% NH4Cl in the drinking water. Cotreatment with HEC 5725 maintained the urinary pH at about main group control levels but also induced increases in serum calcium (males), calcium excretion (males), and calcium oxalate crystal formation (male and female) in the absence of a more alkaline environment. HEC 5725 caused excretion of a highly alkaline urine and disturbances in calcium homeostasis reflected in slightly increased serum calcium together with increased urinary excretion of calcium

For more Non-Human Toxicity Excerpts (Complete) data for Fluoxastrobin (24 total), please visit the HSDB record page.

Fluoxastrobin is stable toward abiotic hydrolysis in sterile buffered solutions at pH 4, 7 and 9 at 50 °C(1). An aqueous lab experiment showed fluoxastrobin to have a photolysis half-life of 3.8 to 4.1 days, corresponding to predicted environmental photolysis half-life range of 18.6 to 21.6 days (solar summer conditions, Phoenix, AZ, in June(2).

Fluoxastrobin's production may result in its release to the environment through various waste streams; its use as a herbicide will result in its direct release to the environment. If released to air, a vapor pressure of 4.5X10-12 mm Hg at 20 °C indicates fluoxastrobin will exist solely in the particulate phase in the atmosphere. Particulate-phase fluoxastrobin will be removed from the atmosphere by wet or dry deposition. If released to soil, fluoxastrobin is expected to have moderate to low mobility based upon a Koc range of 424 to 1582. Volatilization from moist soil surfaces is not expected to be an important fate process based upon an estimated Henry's Law constant of 1.1X10-12 atm-cu m/mole. Biodegradation of fluoxastrobin under aerobic conditions could take several months to several years, depending on the soil texture. If released into water, fluoxastrobin is expected to adsorb to suspended solids and sediment based upon the Koc range. Under aerobic aquatic conditions, a half-life of several days was reported. Volatilization from water surfaces is not expected to be an important fate process based upon this compound's estimated Henry's Law constant. An estimated BCF of 36 suggests the potential for bioconcentration in aquatic organisms is moderate. Fluoxastrobin is stable toward abiotic hydrolysis in sterile buffered solutions at pH 4, 7 and 9 at 50 °C. Aqueous lab experiment showed fluoxastrobin to have a photolysis half-life of 3.8 to 4.1 days, corresponding to predicted environmental photolysis half-life range of 18.6 to 21.6 days (solar summer conditions, Phoenix, AZ, in June) Occupational exposure to fluoxastrobin may occur through inhalation and dermal contact with this compound at workplaces where fluoxastrobin is produced or used. Use data indicate that the general population may be exposed to fluoxastrobin via inhalation and dermal contact with products containing fluoxastrobin. (SRC)

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/

/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/

/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/

Council Directive (EEC) No 414/1991 (Repealed by Reg. EC No 1107/2009 (amended))

Fluoxastrobin is listed in the dataset of EPA Human Health Benchmarks for Pesticides under the Safe Drinking Water Act (40 eCFR 141)

08/44/EC, Reg. (EU) 2018/917, Reg. (EU) 2019/707, Reg. (EU) 2020/869, Reg. (EU) 2021/745, Reg. (EU) 2022/708, Reg. (EU) 2023/918, Reg. (EU) 540/2011

(E)-Fluoxastrobin: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Tolerances are established for residues of fluoxastrobin, including its metabolites and degradates, in or on the commodities in the table below. Compliance with the tolerance levels specified below is to be determined by measuring only fluoxastrobin, (1E)-[2-[[6-(2-chlorophenoxy)-5-fluoro-4-pyrimidinyl]oxy]phenyl](5,6-dihydro-1,4,2-dioxazin-3-yl)methanone O-methyloxime and its Z isomer, (1Z)-[2-[[6-(2-chlorophenoxy)-5-fluoro-4-pyrimidinyl]oxy]phenyl](5,6-dihydro-1,4,2-dioxazin-3-yl)methanone O-methyloxime, calculated as the stoichiometric equivalent of fluoxastrobin. [Table#7645]

Tolerances are established for residues of fluoxastrobin, including its metabolites and degradates, in or on the commodities in the table below. Compliance with the tolerance levels specified below is to be determined by measuring only fluoxastrobin, (1E)-[2-[[6-(2-chlorophenoxy)-5-fluoro-4-pyrimidinyl]oxy]phenyl](5,6-dihydro-1,4,2-dioxazin-3-yl)methanone O-methyloxime, its Z isomer, (1Z)-[2-[[6-(2-chlorophenoxy)-5-fluoro-4-pyrimidinyl]oxy]phenyl](5,6-dihydro-1,4,2-dioxazin-3-yl)methanone O-methyloxime, and its phenoxy-hydroxypyrimidine, 6-(2-chlorophenoxy)-5-fluoro-4-pyrimidinol, calculated as the stoichiometric equivalent of fluoxastrobin. [Table#7646]

Tolerances are established for the indirect or inadvertent residues of fluoxastrobin, including its metabolites and degradates, in or on the commodities in the table below, when present therein as a result of the application of fluoxastrobin to the growing crops listed in paragraph (a)(1) of this section. Compliance with the tolerance levels specified below is to be determined by measuring only fluoxastrobin, (1E)-[2-[[6-(2-chlorophenoxy)-5-fluoro-4-pyrimidinyl]oxy]phenyl](5,6-dihydro-1,4,2-dioxazin-3-yl)methanone O-methyloxime and its Z isomer, (1Z)-[2-[[6-(2-chlorophenoxy)-5-fluoro-4-pyrimidinyl]oxy]phenyl](5,6-dihydro-1,4,2-dioxazin-3-yl)methanone O-methyloxime, calculated as the stoichiometric equivalent of fluoxastrobin. [Table#7647]

Fluoxastrobin is considered a novel strobilurin analog (other strobilurin fungicides include azoxystrobin, dimoxystrobin, kresoxim-methyl, metominostrobin, orysastrobin, picoxystrobin, pyraclostrobin, and trifloxystrobin). The biochemical mode of action of strobilurins consists of interaction with the ubiquinone binding site of the mitochondrial bc1 complex (complex III) in fungal cells, thereby preventing the oxidation of ubihydroquinone and the transfer of electrons to cytochrome c. Interrupting the electron transport chain in this way prevents oxidative phosphorylation, thus causing a severe reduction in the availability of ATP, the main energy currency of the cell. The shortage of energy has a very wide range of biochemical consequences, such as the breakdown of essential membrane potentials and concentration gradients and the inhibition of nucleic acid and protein biosynthesis. Fungal spore germination, mycelial growth and the development of infection structures are thus prevented.

The metabolism of (chlorophenyl-UL-(14)C)fluoxastrobin or (methoxyiminotolyl-UL-(14)C)fluoxastrobin /was studied/ in laying hens. The test substance was administered orally to six hens at 187 ppm or 198 ppm in the diet once per day for three consecutive days; the dose levels represent exaggeration rates of 75,000x and 79,000x, respectively. Fluoxastrobin and its Z-isomer were found to be major residues in hen eggs, fat, and muscle (11- 48% TRR) but were found in smaller quantities in hen liver (0.31-6.8% TRR). Metabolites identified at >10% TRR in hen commodities were HEC5725-phenoxy-hydroxypyrimidine (eggs at 25% TRR, hen liver at 21% TRR, hen muscle at 35% TRR, and hen fat at 21% TRR), HEC5725-2-chlorophenol (up to 23% TRR in eggs and up to 12% TRR in liver), and HEC5725- salicylic acid (eggs at 12% TRR). Based on the results of the studies, the petitioner proposed that fluoxastrobin is metabolized in hens via: (i) hydroxylation of the chlorophenyl ring to mono- and dihydroxy isomers; (ii) hydroxylation of the dioxazine ring followed by oxidative ring opening and further degradation of the dioxazine ring; (iii) oxidative demethylation of the oximether group and cleavage of this group to the ketone and alcohol metabolites; (iv) cleavage of the ether group in the pyrimidine moiety to HEC5725-2-chlorophenol or HEC5725-phenoxyhydroxy-pyrimidine and methoxyiminotolyl-dioxazine ring and methoxyiminotolyl ring metabolites; and (v) conjugation of the hydroxyl groups to glucuronic acid and sulfate conjugates. The metabolism leads finally to the formation of HEC5725-2-chlorophenol, its sulfate conjugate, salicylic acid, 2-OHmandelic acid, and HEC5725-ketocarboxylic acid.

The metabolism of (methoxyiminotolyl-ring-UL-(14)C)fluoxastrobin and (chlorophenyl-UL-(14)C)fluoxastrobin in lactating goats /was investigated/. The test substance was administered orally to a single goat at 180 ppm (methoxyiminotolyl label) or 265 ppm (chlorophenyl label) in the diet once per day for three consecutive days; the dose levels represent exaggeration rates of 15x and 22x, respectively. Fluoxastrobin and its Z-isomer were found to be major residues in goat fat (12-46% TRR) but were found in smaller quantities in milk, goat muscle, liver, and kidney (0.31-6.8% TRR). Metabolites identified at >10% TRR in goat commodities were HEC5725-phenoxyhydroxypyrimidine (milk at 11% TRR, eggs at 25% TRR, goat muscle at 53% TRR, goat kidney at 25% TRR, goat fat at 29% TRR), HEC5725-2-cyanophenol-SA (milk at 23% TRR and goat kidney at 15%), HEC5725-dioxazinyl-alcohol-derivative (goat liver at 16% TRR), HEC5725-di- OH-diene-pyrimidine-OH (milk at 21% TRR), and HEC5725-hydroxyphenyl (goat liver at 11% TRR and goat fat at 13% TRR). Based on the results of the goat metabolism studies, the petitioner proposed that fluoxastrobin is metabolized in goats via: (i) hydroxylation of the chlorophenyl ring to mono- and dihydroxy isomers; (ii) bis hydroxylation and reduction of the chlorophenyl ring to dihydroxy dien E-isomers; (iii) hydroxylation of the dioxazine ring followed by oxidative ring opening and further degradation of the dioxazine ring; (iv) oxidative demethylation of the oximether group and cleavage of this group to the ketone and alcohol metabolites; (v) cleavage of the ether group in the pyrimidine moiety to HEC5725-2-chlorophenol and HEC5725-des-chlorophenyl or to HEC5725-phenoxy-hydroxy-pyrimidine and HEC5725-des-pyrimidine; (vi) bis hydroxylation and reduction of the chlorophenyl ring of HEC5725-phenoxy-hydroxypyrimidine to dihydroxy dien E-isomers; and (vii) conjugation of the hydroxyl groups to glucuronic acid and sulfate compounds.

A study was conducted in male rats to assess the metabolism and disposition of (pyrimidine-2-(14)C)HEC 5725 (Fluoxastrobin; >98% radiochemical purity, batch no. KML2621-A) and non-radiolabeled HEC 5725 (/Fluoxastrobin/ 98.8% chemical purity, batch no. M00358) over 48 hours following a single oral dose of 1 mg/kg. A whole-body autoradiography study over a 168-hour period was also conducted in male and female rats given a single 3 mg/kg oral dose of (pyrimidine-2-(14)C)HEC 5725 (radiochemical purity >99%, lot no.12216/1). ... Metabolite characterization studies of (pyrimidine-2-(14)C)HEC 5725 indicated that the test article is extensively metabolized. The urinary and fecal metabolites accounted for 57-61% of the administered dose. Eight components, representing about 7% of the 1 mg/kg dose, were identified in the 48-hour urine samples. These metabolites were primarily hydroxylation/ conjugation products. No parent compound was detected in the urine. Twelve metabolites and parent compound were detected in the feces. Fecal metabolites were also primarily hydroxylation products, the most prevalent being HEC 5725-di-OH, isomer 2 (11.6% of the dose), HEC5725-di-OH-dioxazine-OH, isomer 2 (9.3% of the dose), and HEC5725-E-des- chlorophenyl (7.2% of the dose). All fecal radioactivity was accounted for by identified metabolites and parent compound being approximately 54% and 1%, respectively, of the administered dose. Other metabolism/disposition studies on (methoxyiminotolyl-ring-UL-(14)C) HEC 5725 ... have shown that biliary contributions account for most fecal radioactivity and that the metabolism of the test article is not a function of bacterial flora. The results of these studies are consistent with the proposed metabolism pathway.

A metabolism and kinetics study was conducted in which young male and female Wistar rats (4/sex/group) were given a single (1 mg/kg or 100 mg/kg) dose of (methoxyiminotolyl-ring-UL-(14)C)HEC5725 (Fluoxastrobin; lot nos. 11675/1, 12250/1, and 12250/17; >99% radiochemical purity). For multiple-dose experiments, rats received 14 consecutive daily gavage doses (1 mg/kg) of non-labeled HEC5725-E-isomer (lot no. M00358, 98.8% purity) followed by a single dose (1 mg/kg) of radiolabeled test article. Biliary excretion was assessed using an additional group of 12 male rats with bile cannulae. Metabolism and disposition, including plasma kinetics, were determined up to 72 hours post dose. ... HEC5725 was extensively metabolized as shown by the extensive metabolite profiles from urine, feces and bile and the relative absence of parent compound (except in the feces of rats given the 100 mg/kg dose). There were no significant qualitative or quantitative differences in metabolite profiles among the test groups or between males and females. The urinary metabolites were primarily the result of cleavage between the second and third rings of the parent compound. Biliary metabolites were primarily products resulting from cleavage of rings 2, 3 and 4, and subsequent hydroxylation, methoxylation, and conjugation with glucuronic acid. HEC5725-E-des-chlorophenyl and HEC5725-des-chlorophenyl-dioxazine-OH were the major metabolites in all excretion matrices. Some of the rat metabolites seem to be in common with metabolites in studies from lactating goat (e.g., HEC5725-di-OH and its dioxazine-OH, HEC5725-E-des-chlorophenyl and its derived ketone, dioxazine-OH, and glycol, in addition to several dioxazine phenyl two ring metabolites) and laying hen (e.g., several glucuronide conjugates of HEC5725- including mono- and di-OHGA, and oxime-GA in addition to mono- and bi-ring fragments including dioxazine-oxime, 2- cyanophenol, and salicylic acid).

A study was conducted in male rats to assess the metabolism and disposition of (chlorophenyl-UL-(14)C)HEC 5725 (Fluoxastrobin; >99% radiochemical purity, batch no. 12712/1, 12712/5 for radioisotopes, 98.9% chemical purity, batch no. M0358 or non-labeled) following a single oral dose of 1 mg/kg. A whole-body autoradiography study was also conducted in male and female rats given a single 3 mg/kg oral dose. Additionally, the metabolism and disposition of the metabolite, (phenyl-UL-(14)C)2-chlorophenol (>98% radiochemical purity, lot no. 12071/1), was examined in male rats give a single 5 mg/kg oral dose. Recovery of administered radioactivity was an acceptable 91-102% among the reviewed studies. Results of the Tier 1 study clearly indicated that (chlorophenyl-UL-(14)C)HEC 5725 (Fluoxastrobin) was rapidly absorbed and metabolized by male rats following a single 1 mg/kg oral dose. Excretion and tissue/organ burden data showed that absorption was nearly 100%. Peak plasma concentrations were achieved within 30 minutes and plasma clearance was rapid. Approximately 77% of administered radioactivity was excreted in the feces and about 14% was excreted in the urine. Excretion via expired air was < or = 0.2%. Overall excretion of administered radioactivity was >90% and complete within 24 hours. Bile duct cannulation experiments revealed that nearly 100% of the fecal radioactivity was contributed by the bile in the form of hydroxylation, methylation, and conjugation products. Metabolite characterization efforts indicated that HEC5725 was extensively metabolized primarily via hydroxylation and subsequent methylation, followed by glucuronide or sulfate conjugation. Approximately 19 fractions were identified in the 24-hour bile samples from rats dosed with the (chlorophenyl-UL-(14)C)HEC5725. These metabolites collectively represented approximately 44% of the administered 1 mg/kg dose with HPLC characterized metabolites and unidentified polar compounds accounting for a an additional

A study was conducted in male rats to assess the metabolism and disposition of (pyrimidine-2-(14)C)HEC 5725 (Fluoxastrobin; >98% radiochemical purity, batch no. KML2621-A) and non-radiolabeled HEC 5725 (/Fluoxastrobin/ 98.8% chemical purity, batch no. M00358) over 48 hours following a single oral dose of 1 mg/kg. A whole-body autoradiography study over a 168-hour period was also conducted in male and female rats given a single 3 mg/kg oral dose of (pyrimidine-2-(14)C)HEC 5725 (radiochemical purity >99%, lot no.12216/1). Recovery of administered radioactivity in the initial study was 84.9-86.7% of the administered dose ... .. In the whole-body autoradiography experiment, recovery of administered radioactivity was 104-112%. Both studies affirmed the rapid absorption and complete excretion of pyrimidine-labeled HEC 5725. Peak plasma concentration was attained at 6-8 hours following dosing in the initial metabolism/ disposition study. Excretion via the feces was the major route of elimination (72-73% of the dose over 48 hours in the 48 hour study) and 94-99% of the dose over the 168-hour duration wholebody autoradiography study. Renal excretion was a secondary route (12- 16%), and elimination of radioactivity via expired air was inconsequential (approximately 0.1%) but confirmed stability of the label. Tissue/carcass burdens accounted for about 1% of the administered radioactivity at 48 hours post dose. Most of this radioactivity was associated with the liver, skin (each approximately 0.2%) and gastrointestinal tract (approximately 0.4%). Autoradiography experiments confirmed that radioactivity was greatest in organs and tissues associated with absorption/ excretory function (e.g., gastrointestinal tract, liver, kidneys). Time-course analysis indicated that test material and/or metabolites reached greatest concentrations within 1 hour of dosing and decreased rapidly thereafter. For all tissues/organs, radioactivity residue was approaching or below LOD or LOQ at 168 hour

A metabolism and kinetics study was conducted in which young male and female Wistar rats (4/sex/group) were given a single (1 mg/kg or 100 mg/kg) dose of (methoxyiminotolyl-ring-UL-(14)C)HEC5725 (Fluoxastrobin; lot nos. 11675/1, 12250/1, and 12250/17; >99% radiochemical purity). For multiple-dose experiments, rats received 14 consecutive daily gavage doses (1 mg/kg) of non-labeled HEC5725-E-isomer (lot no. M00358, 98.8% purity) followed by a single dose (1 mg/kg) of radiolabeled test article. Biliary excretion was assessed using an additional group of 12 male rats with bile cannulae. Metabolism and disposition, including plasma kinetics, were determined up to 72 hours post dose. An autoradiography study ... assessed disposition of (methoxyiminotolyl-ring-UL-(14)C)HEC5725 (Fluoxastrobin; lot nos. 12250/1, and 12250/37; >99% radiochemical purity) in male and female rats over 48 hours following a single 3 mg/kg gavage dose. Mass balance for administered radioactivity in all experiments was an acceptable 91-107%. Excretion profiles and plasma concentration data showed that HEC5725 was rapidly and thoroughly absorbed following single or multiple low (1 mg/kg) doses (tmax of 0.4-1.4 hrs) but absorption appeared to be saturated at the 100 mg/kg dose (tmax of 5.4-8.0 hrs). Limited absorption was reflected by the AUC values (54.10 - 61.30 ug/mL/hr for the high dose groups vs. 1.18 - 1.52 ug/mL/hr for the low and multiple-dose groups), and by Cmax values that were 14-33 fold greater than the low-dose groups. Plasma elimination was biphasic with an initial phase at 0.7-3.5 hrs for the low single or multiple dose groups and 2.3-4.1 hrs for the high-dose groups and a secondary phase at approximately 10 hours and 7 hours for the low and high-dose groups, respectively. Plasma concentration-time plots were suggestive of enterohepatic circulation but this was minimal and still allowed for relatively rapid and complete excretion of administered radioactivity. Distribution and kinetic

A study was conducted in male rats to assess the metabolism and disposition of (chlorophenyl-UL-(14)C)HEC 5725 (Fluoxastrobin; >99% radiochemical purity, batch no. 12712/1, 12712/5 for radioisotopes, 98.9% chemical purity, batch no. M0358 or non-labeled) following a single oral dose of 1 mg/kg. A whole-body autoradiography study was also conducted in male and female rats given a single 3 mg/kg oral dose. Additionally, the metabolism and disposition of the metabolite, (phenyl-UL-(14)C)2-chlorophenol (>98% radiochemical purity, lot no. 12071/1), was examined in male rats give a single 5 mg/kg oral dose. Recovery of administered radioactivity was an acceptable 91-102% among the reviewed studies. Results of the Tier 1 study clearly indicated that (chlorophenyl-UL-(14)C)HEC 5725 (Fluoxastrobin) was rapidly absorbed and metabolized by male rats following a single 1 mg/kg oral dose. Excretion and tissue/organ burden data showed that absorption was nearly 100%. Peak plasma concentrations were achieved within 30 minutes and plasma clearance was rapid. Approximately 77% of administered radioactivity was excreted in the feces and about 14% was excreted in the urine. Excretion via expired air was < or = 0.2%. Overall excretion of administered radioactivity was >90% and complete within 24 hours. Bile duct cannulation experiments revealed that nearly 100% of the fecal radioactivity was contributed by the bile in the form of hydroxylation, methylation, and conjugation products. ...

A preliminary study was conducted in which a single 20 uCi (200 ug) dose of (14)C HEC 5725 (/fluoxastrobin/ lot no. 12250/39, purity >99%) was administered intravenously or dermally (EC 100 formulation) to one male rhesus monkey. The intravenous dose served as a reference for 100% bioavailability. For the main study a single 15 uCi (150 ug) dose of (14)C HEC 5725 (lot no. 12250/39, purity >99%) was administered dermally (EC 100 formulation) to five male rhesus monkeys. The dermal application was for eight hours. Excreta were monitored for up to 192 hours (intravenous dose) or 120 hours (dermal application). ... Actual doses were 195 ug (iv), 172 ug (preliminary dermal), and 148 ug (main dermal). These doses correspond to 60.9 ug/kg, 7.17 ug/ sq cm, and 6.12 ug/ sqcm; only 2.5, 14, and 1% from nominal, respectively. Radioactivity mass balances for the respective test groups were acceptable at 94.0, 102.0, and 93.4%. Following intravenous administration, 52.99% of the administered radioactivity was excreted via the urine, 19.91 via feces, and an additional 21.1% was recovered from cage debris/rinses over the 192-hour experimental period. Approximately 93% of excretion in the urine occurred by 48 hours. Fecal excretion of radiolabel following intravenous administration, although significant (19.91%), was approximately 37.6% of that for urine. Following the 8-hour dermal application, the majority of radioactivity was associated with the dermal swabs and the extracts of those swabs (approximately 84.3-88.4% of applied radioactivity). Only 2.7-12.9% of the radioactivity was associated with the cover material affirming the investigators' contention that most of the applied dose was available for absorption and not bound to the appliance materials. The results of the preliminary study clearly showed that following intravenous administration allowing for 100% bioavailability, HEC 5725 is rapidly and nearly totally excreted in the urine and feces within 48 hours. Following an

Fungicides (strobilurin fungicides)

For fluoxastrobin (USEPA/OPP Pesticide Code: 028869) ACTIVE products with label matches. /SRP: Registered for use in the U.S. but approved pesticide uses may change periodically and so federal, state and local authorities must be consulted for currently approved uses./

Fungicide

For peanuts, potatoes, turf, and tuber and leafy vegetables

Fluoxastrobin is a ... strobilurin-type fungicidal active ingredient (a.i.) for the control of fungal diseases such as early blight, late blight, leaf spots, leaf rust, and Rhizoctonia solani. Fluoxastrobin has been registered for foliar use on peanuts, tuberous and corm vegetables, leaf petiole vegetables, fruiting vegetables, and turf, as well as seed treatment for potato, peanut and turf. Turf applications are labeled for professional pest control operators only, not for homeowners.

This is a man-made compound that is used as a pesticide.

Emulsifiable concentrate; flowable concentrate for seed treatment.

PREMIX PARTNERS: Prothioconazole; Trifloxystrobin.

Disarm G Fungicide (Arysta Lifescience North America, LLC.) 0.25% Fluoxastrobin

Disarm C Fungicide (Arysta Lifescience North America, LLC.) 2.44% Fluoxastrobin, 38.4% Chlorothalonil

For more Formulations/Preparations (Complete) data for Fluoxastrobin (8 total), please visit the HSDB record page.